7 / 22
•
No randomized phase III studies to compare biologicals in fast progressors (PFS<3-4 months)
•
Based on inclusion criteria of the Bv, Aflibercept and Ramucirumab trials: Aflibercept and
Ramucirumab must be considered
•
Aflibercept is only anti-VEGF Agent with benefit in terms of RR and with reported data on BRAF in
2nd- Line
1.Giantonio BJ, et al.
J Clin Oncol
. 2007;25:1539-44
; 2.
Van Cutsem et al.
J Clin Oncol
. 2012;30:3499-506; 3.
Tabernero et al.
Lancet Oncol
. 2015;16:499-508
BRAF
MUTANT CRC: TIME IS RUNNING OUT!